Lindt & Spruengli Increases Sales, But Sees Slowdown Ahead
By Nina Kienle
Chocoladefabriken Lindt & Spruengli reported increased sales for 2023, with strong organic growth in North America that allowed it to offset currency headwinds, but said it expects slower growth in 2024.
The Swiss chocolatier said on Tuesday that its preliminary results show an increase its 2023 sales of 4.6% compared with the prior year to 5.20 billion Swiss francs ($6.08 billion), offsetting a negative currency effect of 5.4%. Sales grew 10% on an organic basis.
All regions contributed to sales growth in 2023, with double-digit growth in North America and the rest of the world region, which includes the company's operations outside Europe and North America, Lindt & Spruengli said.
The company said its is confident in meeting its 2023 goal of achieving an operating profit margin of around 15.5% compared to the 15.0% of the previous year.
For 2024, Lindt & Spruengli forecasts organic sales growth of 6% to 8% and an increase in operating profit margin of 20-40 basis points, both ranges in line with the group's medium to long-term target range, it said.
Full-year results for 2023 are expected to be reported on March 5, the company said.
Write to Nina Kienle at nina.kienle@wsj.com
(END) Dow Jones Newswires
January 16, 2024 03:08 ET (08:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?